2023 article

CRISPR-Cas Biochemistry and CRISPR-Based Molecular Diagnostics

Weng, Z., You, Z., Yang, J., Mohammad, N., Lin, M., Wei, Q., … Zhang, Y. (2023, February 14). ANGEWANDTE CHEMIE-INTERNATIONAL EDITION.

By: Z. Weng*, Z. You *, J. Yang *, N. Mohammad n , M. Lin *, Q. Wei n , X. Gao *, Y. Zhang *

author keywords: Amplification-Free Detection; Biosensors; CRISPR-Cas Biochemistry; Molecular Diagnostics; SARS-Cov-2
MeSH headings : Humans; COVID-19; CRISPR-Cas Systems; Pathology, Molecular; SARS-CoV-2; MicroRNAs; Biosensing Techniques; COVID-19 Testing
TL;DR: Four ongoing research hotspots in molecular diagnostics-target preamplification-free detection, microRNA (miRNA) detection, non-nucleic-acid detection, and SARS-CoV-2 detection-are also covered. (via Semantic Scholar)
UN Sustainable Development Goal Categories
Source: Web Of Science
Added: March 13, 2023

AbstractPolymerase chain reaction (PCR)‐based nucleic acid testing has played a critical role in disease diagnostics, pathogen surveillance, and many more. However, this method requires a long turnaround time, expensive equipment, and trained personnel, limiting its widespread availability and diagnostic capacity. On the other hand, the clustered regularly interspaced short palindromic repeats (CRISPR) technology has recently demonstrated capability for nucleic acid detection with high sensitivity and specificity. CRISPR‐mediated biosensing holds great promise for revolutionizing nucleic acid testing procedures and developing point‐of‐care diagnostics. This review focuses on recent developments in both fundamental CRISPR biochemistry and CRISPR‐based nucleic acid detection techniques. Four ongoing research hotspots in molecular diagnostics‐target preamplification‐free detection, microRNA (miRNA) testing, non‐nucleic‐acid detection, and SARS‐CoV‐2 detection‐are also covered.